<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915486</url>
  </required_header>
  <id_info>
    <org_study_id>CS I-020201/01</org_study_id>
    <nct_id>NCT00915486</nct_id>
  </id_info>
  <brief_title>A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers</brief_title>
  <acronym>DFU</acronym>
  <official_title>A Randomized, Multi-center, Controlled, Parallel Group, Dose Finding Study of the Efficacy and Safety of Topically Applied I-020201 as an Adjunct to Good Standard-of-care Versus Good Standard-of-care Alone in Patients With Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuros Biosurgery AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuros Biosurgery AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although major improvements in the management and treatment of diabetic foot ulcers have been
      made, the clinical and financial burden of such long-term wounds is still high and is likely
      to increase as the general population ages. The large population affected by diabetic foot
      ulcers and the high rates of failure ending with amputation even with the best therapeutic
      regimens have resulted in the development of new therapies. I-020201 is a bioactive therapy
      intended for topical treatment of hard-to-heal diabetic foot ulcers, stimulating the
      granulation tissue formation. This study aims to evaluate the safety and efficacy of I-020201
      in adjunct to good standard of care in patients with chronic diabetic foot ulcer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction in ulcer surface area</measure>
    <time_frame>4 weeks after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards)</measure>
    <time_frame>At 12 and 16 weeks after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards)</measure>
    <time_frame>Within the whole study period (28 weeks after treatment start)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure (full re-epithelialization with confirmation 4 weeks afterwards).</measure>
    <time_frame>At any time during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment failure defined as &lt;30% decrease in ulcer size</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients with ulcer recurrence</measure>
    <time_frame>Up to 16 and 28 weeks after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events (systemic and at the target ulcer) and all AEs/SAEs</measure>
    <time_frame>During the whole study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systemic PDGF-AB and antibody levels against TG-PDGF.AB and aprotinin</measure>
    <time_frame>At 1, 4, 12, 16 and 20 weeks after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs, body weight, physical examination and laboratory parameters</measure>
    <time_frame>Throughout the study and 28 weeks after treatment start</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Good Standard of Care (GSoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSoC + vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSoC + I-020201 (33microg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSoC + I-020201 (100microg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSoC + I-020201 (300microg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Good Standard of Care (GSoC)</intervention_name>
    <description>Procedural treatment twice per week</description>
    <arm_group_label>Good Standard of Care (GSoC)</arm_group_label>
    <arm_group_label>GSoC + vehicle</arm_group_label>
    <arm_group_label>GSoC + I-020201 (33microg)</arm_group_label>
    <arm_group_label>GSoC + I-020201 (100microg)</arm_group_label>
    <arm_group_label>GSoC + I-020201 (300microg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical fibrin as an adjunct to GSoC twice per week</description>
    <arm_group_label>GSoC + vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>I-020201</intervention_name>
    <description>Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week</description>
    <arm_group_label>GSoC + I-020201 (33microg)</arm_group_label>
    <arm_group_label>GSoC + I-020201 (100microg)</arm_group_label>
    <arm_group_label>GSoC + I-020201 (300microg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, aged ≥ 18 years

          -  given written informed consent

          -  female of childbearing potential with a negative result from the pregnancy test at
             screening who agrees to use an acceptable birth control method (hormonal or IUD) or
             abstinence throughout the trial

          -  Type 1 or Type 2 Diabetes mellitus with HbA1c =&lt; 12%

          -  with only one diabetic foot ulcer on the foot to be treated on or below the ankle

        Exclusion Criteria:

          -  pregnant or breast-feeding

          -  known or suspected allergies to any of the components of the I-020201

          -  uncontrolled anemia (Hb &lt; 9 g/dL in females and &lt; 10 g/dL in males)

          -  hypoalbuminemia (albumin &lt; 3 g/dL)

          -  overtly infected target ulcer (as judged by investigator)

          -  highly exuding wounds (wounds that require a daily dressing change)

          -  osteomyelitis

          -  systemic infections

          -  acute Charcot foot and severe chronic Charcot deformity

          -  ABPI &lt; 0.7 or ankle systolic pressure &lt; 70 mm Hg

          -  one of the following findings (only 1 out of 3 tests is required):

               -  on Doppler waveform analysis on the dorsalis pedis and posterior tibial arteries
                  a monophasic or biphasic flow (with loss of reverse flow) in either foot artery,
                  or

               -  a toe: brachial index &lt; 0.7, or

               -  transcutaneous oxygen pressure (TcpO2) &lt; 40 mm Hg

          -  suspicion, presence or history of systemic or local cancer or tumor of any kind
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Jamieson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kuros Biosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetologické centrum, I. Interní klinika FN Hradec Králové, Fakultní nemocnice Hradec Králové (21)</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interní klinika 2. Lékařské fakulty UK a FN Motol, Fakultní nemocnice Motol (22)</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lékařský dum Ormiga Angiologická a diabetologická ambulance (20)</name>
      <address>
        <city>Zlín</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddelení diabetologie - Podiatricka ambulance Krajská zdravotní a.s.- Masarykova nemocnice v Ústí nad Labem o.z. (23)</name>
      <address>
        <city>Ústí nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen (01)</name>
      <address>
        <city>Böblingen</city>
        <zip>71031</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach (04)</name>
      <address>
        <city>Karlsbad</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart Bürgerhospital (03)</name>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Tübingen Chirugische Poliklinik (02)</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Közhasznú Non-Profit Kft (35)</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fõvárosi Önkormányzat Egyesített Szent István és Szent László Kórház - Rendelõintézet Sebészeti Osztály (32)</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fővárosi Önkormányzat Szent Imre Kórház Operativ Szakmák Mátrix Szervezete Általános Sebészeti Profil (33)</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esztergom Város Önkormányzat Vaszary Kolos Kórház Sebészeti Osztály (34)</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Oktató Kórház (38)</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Önkormányzat Kórháza Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, 2. Belgyógyászat (31)</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház Érsebészeti Osztály (30)</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE Klinikai Központ Érsebészeti Klinikai Tanszék (36)</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Györgyi Albert Klinikai Centrum (37)</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Naţional de Diabet, Nutriţie şi Boli Metabolice &quot;Prof. Dr. N. C. Paulescu&quot; (42)</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judeţean de Urgenţă Cluj (43)</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judeţean Mureş, Clinica de Dermatologie (40)</name>
      <address>
        <city>Tg Mures</city>
        <zip>540342</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Individual DermaMed (41)</name>
      <address>
        <city>Tg. Mures,</city>
        <zip>540530</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Timisoara (45)</name>
      <address>
        <city>Timisoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital # 13 (11)</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State University of Public Health &quot;City Clinical (17)</name>
      <address>
        <city>Moscow</city>
        <zip>115432</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Diabetes, Russian State Medical University, Moscow City Clinical Hospital # 1 (15)</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Diabetic Foot Endocrinology dispensary (12)</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Clinic of the State Educational Institute of High Professional Education (18)</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Federal Bureau of Medical Social Expertise&quot; (10)</name>
      <address>
        <city>Moscow</city>
        <zip>123448</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Hospital # 81 (14)</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinički centar Srbije, Institut za endokrinologiju, dijabetes i bolesti metabolizma (51)</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Kragujevac (54)</name>
      <address>
        <city>Kragujevac</city>
        <zip>34 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis (50)</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Vojvodina (53)</name>
      <address>
        <city>Novi Sad</city>
        <zip>21 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Centre Valjevo (52)</name>
      <address>
        <city>Valjevo</city>
        <zip>14 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>ulcer</keyword>
  <keyword>topical</keyword>
  <keyword>PDGF</keyword>
  <keyword>GSoC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

